• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Inspira Technologies Oxy B.H.N. Ltd.

    3/19/25 7:20:29 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care
    Get the next $IINN alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001796650
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Inspira Technologies OXY B.H.N. Ltd
    SEC File Number
    001-40303
    Address of Issuer
    HATIDHAR 2
    11TH FLOOR
    RA'ANANA
    ISRAEL
    4366504
    Phone
    972-9-9664488
    Name of Person for Whose Account the Securities are To Be Sold
    Goldwasser Benad
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Ordinary
    Oppenheimer & Co. Inc.
    85 Broad St.
    New York � NY � 10004
    3527026234.002425209603/19/2025
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Ordinary11/02/2021Restricted Stock Units IssuerCheckbox not checked42323711/02/2021N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Goldwasser Benad
    HATIDHAR 2
    RA'ANANA � L3 � 4366504
    Ordinary12/19/20241175711046.88
    Goldwasser Benad
    HATIDHAR 2
    RA'ANANA � L3 � 4366504
    Ordinary01/17/20251175712589.40
    Goldwasser Benad
    HATIDHAR 2
    RA'ANANA � L3 � 4366504
    Ordinary02/18/20251175710608.34

    144: Remarks and Signature

    Remarks
    Under a 10b5-1 sale plan adopted on 05/23/2024
    Date of Notice
    03/19/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    05/23/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Goldwasser Benad

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $IINN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IINN

    DatePrice TargetRatingAnalyst
    11/1/2021$9.00 → $10.00Buy
    Aegis Capital
    8/26/2021$9.00Buy
    Aegis Capital
    More analyst ratings

    $IINN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients

      RA'ANANA, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that the INSPIRA™ ART100 has been approved by Israel's largest healthcare provider to undergo a clinical validation by leading physicians who intend to use the innovative life-support and diagnostic device during organ transplant procedures.  As part of this advancement, Inspira will deploy the U.S. Food and Drug Administration ("FDA") approved INSPIRA ART100 system at one of Israel's renowned medical centers affiliated with the largest health care provider. A team of pioneeri

      5/7/25 8:45:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing

      RA'ANANA, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a major milestone achievement in the in-vivo testing of its next-generation VORTX™ technology. This breakthrough innovation is uniquely designed to oxygenate blood effectively without the trauma associated with conventional hollow fiber technologies. The in vivo testing achieved above 99% gas exchange target at a defined flow rate. The VORTX technology, slated for integration into Inspira's pipeline, including the INSPIRA ART500, aims to transform acute respiratory ca

      4/23/25 8:00:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems

      RA'ANANA, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, April 15, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has received payment from its U.S. distributor, Glo-Med Networks Inc. ("Glo-Med"), for a delivery of its INSPIRA™ ART100 systems, which are cleared by the U.S. Food & Drug Administration ("FDA"). The revenue, in the range of the low hundreds of thousands of dollars, relates to the delivery of the INSPIRA ART100 systems, which have been recently installed at a premier U.S. academic medical center, as previously announced. In addition

      4/15/25 9:15:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care

    $IINN
    Financials

    Live finance-specific insights

    See more
    • Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates

      Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel, March 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2024, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "2024 was a transformative year for Inspira, marked by significant technological advancements and a major regulatory milestone. We successfully obtained 510(k) clearance from the Food and Drug Administration ("FDA") for our INSPIRA™ ART100 system an

      3/11/25 8:30:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • Inspira™ Announces Business Plan Targets

      Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA™ ART (Gen2) RA'ANANA, Israel, June 20, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), (NASDAQ:IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President and co-founder, Mr. Joe Hayon, presented a business plan with targets for the Company's next-generation technologies on a Company conference call today.     On the call, Inspira unveiled plans to build an opportunity for a share of the $19 billion mechanical ventilation market. Inspira's

      6/20/24 9:25:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • Inspira™ to Exhibit the FDA Cleared INSPIRA™ ART100 System at a World-Renowned Event in the Sector

      The event is an opportunity to present and demonstrate new products and technologies to potential customers and strategic partners RA'ANANA, Israel, June 5, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, is proud to announce plans to exhibit the INSPIRA™ ART100 System, recently cleared by the U.S. Food and Drug Administration ("FDA"), at the Extracorporeal Life Support Organization (ELSO) conference in Detroit, Michigan between September 29 to October 1, 2024. This event provides the Company with an opportunity to present the system in front of healthcare representa

      6/5/24 8:30:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care

    $IINN
    SEC Filings

    See more
    • SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

      6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

      5/7/25 9:15:16 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

      6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

      4/23/25 8:05:13 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

      6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

      4/15/25 9:20:03 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care

    $IINN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd.

      SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

      11/14/24 4:08:42 PM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Inspira Technologies Oxy B.H.N. Ltd.

      SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

      2/14/24 3:40:01 PM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd. (Amendment)

      SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

      2/12/24 4:05:09 PM ET
      $IINN
      Medical/Dental Instruments
      Health Care

    $IINN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital reiterated coverage on Inspira Technologies Oxy with a new price target

      Aegis Capital reiterated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $10.00 from $9.00 previously

      11/1/21 12:39:26 PM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • Aegis Capital initiated coverage on Inspira Technologies Oxy with a new price target

      Aegis Capital initiated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $9.00

      8/26/21 10:05:11 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care

    $IINN
    Leadership Updates

    Live Leadership Updates

    See more
    • PESG Report: Inspira Technologies Strengthens its AI-Powered Blood Sensor with new Capabilities, Intends to Share Clinical Findings Soon

      Inspira Technologies* advancement of its AI-powered blood monitoring technology comes amid robust growth in medical technology M&A, with Q3 2024 seeing 275 deals worth $34 billion - a 35% increase year-over-year. The integration of this new oxygenation indicator strengthens the Company's position in both the $2.5 billion blood gas analysis market and, through the FDA-cleared INSPIRA ART100 system, the $19 billion mechanical ventilation market. With clinical evaluations of the HYLA blood sensor underway at Sheba Medical Center and preliminary results reportedly expected in the near future, the Company continues to execute its strategy of combining AI-enhanced monitoring capabilities with inn

      2/6/25 8:27:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • Inspira™ Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors

      RA'ANANA, Israel, Jan. 21, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced the appointment of Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025.     Mr. Parnes brings a wealth of experience and expertise to his new role at Inspira. With a distinguished career spanning over three decades in the technology sector, with a special focus in the medical technology and pharmaceutical industries, Mr. Parnes has consistently demonstrated exceptional leadership and strategic vision. As a serial entrepreneur, Parnes has demonstrated

      1/21/25 8:30:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care
    • In Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil, to Medical Advisory Board

      RA'ANANA, Israel, Dec. 11, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil is a distinguished specialist in cardiac surgery and intensive care medicine. Dr. Gorfil is both the head of the Cardiothoracic Surgery Intensive Care Unit and the Extracorporeal Membrane Oxygenation program at the Department of Cardiothoracic Surgery at Rabin Medical Center, Israel. Dr. Gorfil's expertise are expected to significantly contribute to the

      12/11/23 9:00:00 AM ET
      $IINN
      Medical/Dental Instruments
      Health Care